Alexion Pharma beats by $0.32, beats on revs; raises FY19 guidance, announces new $1 bln share repurchase authorization (99.28)
- Reports Q3 (Sep) earnings of $2.79 per share, excluding non-recurring items, $0.32 better than the S&P Capital IQ Consensus of $2.47; revenues rose 23.0% year/year to $1.26 bln vs the $1.24 bln S&P Capital IQ Consensus.
- In October 2019, the Board of Directors approved a new share repurchase authorization of $1 billion. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares of common stock.
- Co raises guidance for FY19, sees EPS of $10.25-10.40 (Prior $9.65-9.85), excluding non-recurring items, vs. $9.93 S&P Capital IQ Consensus; sees FY19 revs of $4.86-4.89 bln (Prior $4.75-4.8 bln) vs. $4.84 bln S&P Capital IQ Consensus